Alexander Xenakis on for Kripa Deverakonda's questions to Cytokinetics Inc (CYTK) leadership • Q2 2025
Question
An analyst on for Kripa Deverakonda at Truist Securities asked about the market dynamics in China, which may be the first market for approval, and the expected revenue cadence.
Answer
Andrew Callos, EVP & Chief Commercial Officer, explained that aficamtan would initially be a cash-pay product in China until it achieves national reimbursement (NRDL). He projected a slow initial uptake, followed by an acceleration post-reimbursement, and noted the strength of their partner, Sanofi, in that market.